Navigation Links
Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company
Date:8/17/2011

NEW YORK, Aug. 17, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed by the Hadassah University Hospital, Israel's foremost medical research center, announced that its portfolio company Enlivex Therapeutics (92% owned by Hadasit Bio) has completed the recruitment of three out of four groups in its Phase I / II clinical trial using its treatment for the reduction of graft versus host disease (GVHD) in patients undergoing bone marrow transplantation.

Based on the current rate of enrollment and high level of safety observed so far, the trial's enrollment is expected to be completed during the next quarter with a total of 12 patients. The trial is being performed in three of Israel's leading hematology medical centers: Hadassah, Tel - Hashomer and Rambam.

The trial is being performed on bone marrow transplant patients, but the results are also relevant to a number of other autoimmune diseases - in which the individual's immune system targets its own organs - as well as inflammatory diseases - such as Multiple Sclerosis and Inflammatory Bowel Disease.  

An external safety committee meets at the end of each dose group to examine the safety of the treatment and has thus far been impressed by initial results showing this to be a promising treatment method and has consistently approved advancement to the next group, while raising the dose.

The Company previously announced the preliminary results from the earlier stages of this trial.  The treatment continued to show promise after analysis of intermediate results. In terms of efficacy, the Company estimates that, if the results received at the end of the trial are consistent with the data received so far, it will have evidence of a significant improvement in patients' health following the use of its treatment in comparison with the current standard treatments administered.
'/>"/>

SOURCE Hadasit Bio-Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
3. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
4. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 ... presentation, Dr. James L. Sherley, director of the Adult ... attention on an often overlooked and under appreciated unique ... “Asymmetric Self-Renewal by Distributed Stem Cells: Misunderstood in the ... his message to congress participants. He gave the ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 ... into law H.R. 83, the Omnibus and Continuing ... first time, made hydrocephalus a condition eligible to ... Programs (CDMRP) administered by the Department of Defense ... with its allies on Capitol Hill, is celebrating ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... on methyl mercaptan such as its definition, ... also presents product specification, manufacturing process, and ... regions, technology and applications. The analysis also ... survey, marketing channels, industry development trend and ...
(Date:12/24/2014)... The report expects global cell isolation and ... also provides a carefully analyzed data about the vital ... market. , Full Copy of Report @ http://bit.ly/1yUxy0T ... for cell expansion will keep witnessing growth at an ... to be driven by rapid technological advancements, government funding ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... sciences for 2004 and what impact will these have on the ... the land of biotech and pharmaceuticals, the answer could be: , ... cardiovascular side effects and the resultant scrutiny on the FDA for ... the way, the recent Pfizer debacle with Celebrex in the last ...
... Larry Landweber knows networks. The University of Wisconsin-Madison ... forge some of the early international channels of the Internet. ... and its all about finding the right applications to ... WTN from Washington, D.C., where he works for the ...
... competition soon. A coalition of research and metropolitan ... an incubator for start-up biotech companies. , ,The ... new companies in, said representatives of the Milwaukee Biomedical ... attract companies to the area. , ,Guy Mascari, director ...
Cached Biology Technology:The greatest life-science developments of 2004 2The greatest life-science developments of 2004 3The greatest life-science developments of 2004 4The greatest life-science developments of 2004 5The greatest life-science developments of 2004 6The greatest life-science developments of 2004 7Landweber on networks, open source, and NSF budget cuts 2Landweber on networks, open source, and NSF budget cuts 3Landweber on networks, open source, and NSF budget cuts 4Milwaukee research alliance sees need for incubator 2
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December ... of people to eliminate the pain of trying to ... system with their own biometrics fused to their smartphones. ... and passwords, Hoyos Labs , the company that ... that it is offering the app for free. ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... entertainer and security consultant, Apollo Robbins for ... smart wallet.  Apollo Robbins ... 7 th , 2015, demonstrating some of his famous ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the addition of the "The Global ... their offering. ... an overview of the global digital media ... control and monitor piracy by securely and ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
... NY - JDRF said today that it has recognized the ... accelerating the pace of science in understanding the autoimmune attack ... the severe complications of this chronic and life-threatening disease. ... are Dr. Jeffrey A. Bluestone, Director of the Diabetes Center ...
... it much harder to evade justice in future, thanks to an ... tiny tags just 30 microns* in diameter and invisible to ... cartridges. They then attach themselves to the hands or gloves of ... completely. Crucially, some of these ,nanotags, also remain on ...
... United States die every year from uncontrolled infections of ... pushing the boundaries of molecular science to find new ... measure of an immune system protein within 24 hours ... can predict survival in children, yielding a powerful tool ...
Cached Biology News:JDRF announces 2008 Scholar Award recipients 2JDRF announces 2008 Scholar Award recipients 3Guilt on their hands: tiny 'tags' could help to solve and deter gun crime 2Immune system protein accurate predictor of survival in pediatric septic shock 2Immune system protein accurate predictor of survival in pediatric septic shock 3
... Fixed clamp trays and universal trays ... Magnetic drive Shaking speed: ... 25 mm amplitude Clamps ... 2000 ml, including Fernbach flasks ...
... convenient, and efficient Denatured protein concentration following ... spin column to make handling easy. The ... which were electro-eluted in their Denatured condition. ... high binding capacity fo all pH values. ...
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
Biology Products: